


Alturix Limited - Methodological note for HCP/ORDM/HCO disclosure 2025

Data year: 2025

Year of publication: 2026

Contents

1	Definitions	3
1.1	Recipients.....	3
1.2	Kind of ToVs.....	3
2	Disclosure's Scope	3
2.1	Products concerned.....	3
2.2	Company concerned	3
2.3	Excluded ToVs	3
2.4	ToVs date	3
2.5	Direct ToVs.....	3
2.6	Indirect ToVs	3
2.7	Non-monetary ToVs.....	3
2.8	ToVs in case of partial attendances or cancellation and refund	3
2.9	Cross-border activities	3
2.10	R&D	4
2.11	Voluntary disclosure.....	4
3	Specific considerations	4
3.1	Country unique identifier.....	4
3.2	Self-incorporated HCP.....	4
3.3	Multi-year agreements.....	4
3.4	Country specificities.....	4
3.5	Quality Checks	4



ALTURIX®

Version: 11th June 2026
Country: United Kingdom

4	Data protection legal basis	4
4.1	Consent collection	4
4.2	Legitimate interests.....	4
5	Form of disclosure	4
5.1	Date of publication.....	4
5.2	Disclosure platform.....	4
5.3	Disclosure language	5
6	Disclosure financial data	5
6.1	Currency.....	5
6.2	VAT included or excluded	5
6.3	Calculation rules.....	5
7	Additional Information	5

1 Definitions

1.1 Recipients

- Alturix Limited is a non-member company of the ABPI (an EFPIA affiliated organisation) that has agreed to abide by the ABPI Code of Practice, including for the disclosure of transfers of value (TOV) to healthcare professionals (HCPs), other relevant decision makers (ORDMs), healthcare organisations (HCOs) and research and development projects (R&D).

1.2 Kind of ToVs

- Payments have been made for promotional stands and contracted service fees and expenses. Where payment has been made for a promotional stand, this has been included under Event Sponsorship. Where a payment has been made for a promotional stand at an event organised by an HCP's company, the payee has been treated as an HCO.

2 Disclosure's Scope

2.1 Products concerned

- Prescription Only Medicines (POM's)

2.2 Company concerned

- Alturix Limited

2.3 Excluded ToVs

- No ToVs have been excluded.

2.4 ToVs date

- 1st January 2025 – 31st December 2025

2.5 Direct ToVs

- Fee for Service

2.6 Indirect ToVs

- None in year

2.7 Non-monetary ToVs

- No non-monetary ToV has been made

2.8 ToVs in case of partial attendances or cancellation and refund

- Not applicable

2.9 Cross-border activities

- No payments have been made to HCPs or HCOs outside of the United Kingdom

2.10 R&D

- No R&D ToV has been made.

2.11 Voluntary disclosure

- No non-monetary TOV has been made.

3 Specific considerations

3.1 Country unique identifier

- No unique identifiers used.

3.2 Self-incorporated HCP

- Not applicable

3.3 Multi-year agreements

- All payments shown were made in 2025, regardless of when the activity to which the payment relates took place. There are no multi-year contracts in place

3.4 Country specificities

- No TOV has been made in conjunction with another pharmaceutical company

3.5 Quality Checks

- All values disclosed have been cross checked against accounting records

4 Data protection legal basis

4.1 Consent collection

- All HCPs paid have agreed to named disclosure via a clause in their contracts which is signed on engagement

4.2 Legitimate interests

- All HCPs paid have agreed to named disclosure via a clause in their contracts which is signed on engagement

5 Form of disclosure

5.1 Date of publication

- 31/03/2026

5.2 Disclosure platform

- Disclosure UK – www.disclosureuk.org.uk

5.3 Disclosure language

- English

6 Disclosure financial data

6.1 Currency

- All payments disclosed were made in GBP from Alturix Limited

6.2 VAT included or excluded

- All payments are shown net of any VAT that was paid

6.3 Calculation rules

- Based upon an hourly fee under the ABPI guidance on fair market value.

7 Additional Information

- Not applicable